Seraxis logo
VerifiedBiotechnology Research· Founded 2013

Seraxis

Seraxis is bringing transformative therapies to the millions of people worldwide struggling with the management of insulin-requiring diabetes and the associated life-threatening complications. Seraxis’ lead program, SR-02, is a novel islet replacement therapy for patients of insulin-requiring diabetes with concurrent immunosuppression therapy. This therapy is the foundation of Seraxis follow-on therapies for patients without immune suppression. Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, the T1D Fund and others are investors in Seraxis.

7-day free trial · no credit card

HeadquartersGermantown, United StatesEmployees16(11 to 50)Annual revenue$1M to <$10MFounded year2013Websiteseraxis.comLinkedIn profileLinkedIn

Verified contacts

23

available on Kipplo

LinkedIn employees

16

11 to 50 range

Open roles

no listings

Distinct roles

17

indexed titles

Tech stack

1

tools in use

Monthly traffic

68

organic / mo

Sign up free to see all 23 verified contacts at Seraxis

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Decision-makers and verified team members

23 contacts with verified email or phone · masked until revealed.

Sign up free →

Top roles at Seraxis

17 distinct titles indexed · top 10 shown.

  • 2cell culture scientist
  • 2qc scientist
  • 2quality assurance specialist
  • 2quality control scientist
  • 1(,)
  • 1board observer
  • 1cell cuture scientist
  • 1chairman of the board of directors, compensation committee member
  • 1chief business officer
  • 1chief corporate development officer
  • +7more titles

Sign up to unlock all 23 contacts at Seraxis

Free for 7 days · 50 credits · no card · only pay for verified records.

Sign up free

Sign up to reveal 23 verified contacts at Seraxis

7-day trial · no credit card · cancel anytime · only pay for verified records.

Trusted by sales, marketing, and GTM engineering teams.

Seraxis | Kipplo Discover